Literature DB >> 30256339

Surgical Management of Atypical Femur Fractures Associated With Bisphosphonate Therapy.

Michael Githens1, Matthew R Garner, Reza Firoozabadi.   

Abstract

Atypical femur fractures associated with long-term bisphosphonate use can be challenging injuries to manage. Not only do they have a prolonged healing time and increased rate of nonunion as compared to typical femur fractures, intraoperative complications are not infrequent and can be catastrophic. Given the pathologic nature of these fractures, a multidisciplinary approach to the patient's care is necessary. Treatment begins with medical optimization and careful surgical planning. Radiographic characteristics of the fracture and femoral osteology dictate reduction strategy, adjunctive surgical techniques, and implant choice. Intraoperative complications including malreduction, iatrogenic fracture, and fracture propagation can be avoided with thoughtful planning. The purpose of this article is to discuss the technical aspects of surgical management of atypical femur fractures. We also discuss management of intraoperative complications and treatment failure. Finally, we provide an update on recommendations for postoperative medical treatment and management of the contralateral femur.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30256339     DOI: 10.5435/JAAOS-D-16-00717

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  2 in total

1.  Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy.

Authors:  Dávid Dózsai; Tamás Ecseri; István Csonka; István Gárgyán; Péter Doró; Ákos Csonka
Journal:  J Orthop Surg Res       Date:  2020-09-15       Impact factor: 2.359

2.  Atypical periprosthetic femoral fractures after arthroplasty for fracture are at high risk of complications.

Authors:  Tomonori Baba; Masataka Uchino; Hironori Ochi; Takuya Ikuta; Yoshitomo Saita; Hiroshi Hagino; Hiroaki Nonomiya; Seiya Jingushi; Takayuki Nakajima; Yasuhisa Ueda; Kaneko Kazuo
Journal:  Sci Rep       Date:  2021-07-13       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.